FDA Announces Pilot Program to Improve Transparency of Drug Clinical Trial Data

U.S. Food and Drug Administration (FDA) Commissioner, Scott Gottlieb, MD, recently announced a new pilot program to improve transparency around clinical trial information to spur innovation and scientific analysis for new drugs. The Agency plans to continue sharing information around product approvals and improve its transparency regarding clinical study reports that may be advantageous to patients, providers and scientists. Some information on drug approvals is currently shared with the public, but according to complaints, it is done through a complex and confusing format. The FDA plans to initiate talks with drug companies to assess their willingness to participate in the program and then solicit public feedback once the pilot is completed.

Keywords: ACC Advocacy, Drug Approval, United States Food and Drug Administration, Pilot Projects, Drug Evaluation, Information Dissemination, Consumer Product Safety

< Back to Listings